PDCD1 and cancer: In recent years, immune checkpoint inhibitor (ICI) therapy targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has considerably advanced treatment across a range of cancers [8].